Raymond James initiated coverage of Tyra Biosciences (TYRA) with a Strong Buy rating and $35 price target Tyra’s unique SNAP development platform, as validated with the first discovery candidate, TYRA-300, is “potentially best-in-class,” says the analyst, who sees “multi-billion-dollar revenue potential” in the indications being investigated.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Bioscience’s Promising Developments in NMIBC and Achondroplasia Drive Buy Rating
- Tyra Bioscience Begins Phase 2 Study for Achondroplasia
- Tyra Biosciences says first child dosed in BEACH301 trial
- Tyra Bioscience: Strategic Advancements and Financial Stability Justify Buy Rating
- Tyra Bioscience: Promising Clinical Trials and Financial Stability Justify Buy Rating